Matrixyl: research

A topical cosmetic peptide with limited human evidence for making fine lines less visible.

Also called: Palmitoyl pentapeptide-4, Pal-KTTKS, Palmitoyl-Lys-Thr-Thr-Lys-Ser, C16-KTTKS, Palmitoyl pentapeptide-3, former name.

Cosmetic peptides · Lipid-linked collagen-fragment signal peptide.

15 reported human investigations, including mixtures and patch tests. Older supplier cohorts may overlap; the evidence for isolated peptide effects remains limited.

Studies

• 2005: 3 ppm wrinkle trial. rct, n=93, White women aged 35–55 with facial sun damage.. A 3 ppm cream improved wrinkle appearance versus its matching moisturizer. (source)
• 2023: crow's feet comparison. rct, n=21, Indonesian women aged 26–55, skin types III–V.. Scores fell in all groups; this small trial did not establish superiority. (source)
• Patent: 50 ppm cream. rct, n=15, 15 women aged 35–63.. A patent reports wrinkle changes with 50 ppm cream and limited methods. (source)
• 2005: moisturizer conference abstract. rct, Women aged 35–65; review reports 60 panelists per product.. An abstract reports texture changes with a mixed 3 ppm moisturizer. (source)
• Older study: 49 women. cohort, n=49, 49 women in a manufacturer-sponsored double-blind comparison.. A review reports wrinkle and biopsy changes; original data were not recovered. (source)
• Older study: retinol comparison. cohort, n=16, 16 volunteers in an older manufacturer comparison.. A review reports similar changes to retinol; equivalence was not established. (source)
• Supplier report: 25-person comparison. cohort, n=25, 25 volunteers, mean age 55.6, in a supplier split-face study.. Both blends improved versus baseline; they did not clearly differ. (source)
• 2004: radiotherapy skin-care cream. rct, n=20, 20 women receiving breast radiotherapy.. A mixed Matrixyl cream had no advantage over dexpanthenol lotion. (source)
• 2009: mixed creams, study 1. rct, n=42, Women aged 30–70 with moderate to marked eye-area wrinkles.. Mixed products improved smoothness; peptide contribution is unknown. (source)
• 2009: mixed creams, study 2. rct, n=35, Women aged 30–70 with moderate to marked eye-area wrinkles.. Results differed by product in a second mixed-product study. (source)
• 2010: mixed regimen versus tretinoin. rct, n=196, Women aged 40–65 with moderate to moderately severe eye-area wrinkles.. Mixed-regimen results cannot establish that Matrixyl alone works like tretinoin. (source)
• Safety: 48-hour patch test. single-arm, n=10, 10 volunteers in a supplier irritation test.. One participant had barely visible redness after an occluded mixture. (source)
• Safety: repeated patch test. single-arm, n=51, 51 volunteers in a supplier repeat-exposure test.. No irritation or sensitization was reported in this patch test. (source)
• 2025: neck and upper-lip wrinkles. cohort, n=43, White women aged 50–70, mean 62, with visible neck and upper-lip wrinkles.. A supplier report describes wrinkle changes, with undisclosed strength and limited trial methods. (source)
• 2026: mixed serum and facial device. case-report, n=1, One 41-year-old woman.. A mixed serum/device case cannot show a peptide-specific benefit. (source)
• Mechanism: collagen-fragment signal. in-vitro, Cultured connective-tissue cells.. Unmodified KTTKS stimulated collagen and fibronectin production. (source)
• Mechanism: lipid-linked peptide. in-vitro, Human skin and corneal cells grown in a lab.. Pal-KTTKS increased collagen production in cultured cells. (source)
• Delivery: excised mouse skin. in-vitro, Removed mouse skin and skin extracts.. Pal-KTTKS entered skin layers; full-thickness passage was not quantifiable. (source)
• Delivery: microneedles in removed skin. in-vitro, Excised human skin in diffusion cells.. Microneedles increased peptide entry into removed skin. (source)
• Animal study: wound patches. animal, Animals with experimental skin wounds.. Peptide patches and cream changed wound healing in animals. (source)
• Mechanism: peptide structure. in-vitro, Human skin fibroblasts grown in a lab.. Cell responses depended on peptide concentration and structure. (source)
• 2026: broader peptide meta-analysis. meta-analysis, n=1341, 1,341 participants across 19 peptide trials.. The pooled result mainly reflects oral collagen, not topical Matrixyl. (source)

Gaps: Most studies are short, small, industry-linked or test mixtures. No reliable long-term effect size is established. The 2005 primary full tables were not recovered; do not copy unsourced wrinkle-reduction percentages. Older 49- and 16-person studies rely on a review. Their original data and possible cohort overlap remain unresolved. No pregnancy, breastfeeding or under-18 safety program found. Precautionary screens are not proof of fetal harm. No established human injection, oral or nasal dose, systemic half-life or systemic drug-interaction study found. Highest verified wrinkle-study concentration is 50 ppm in a patent; the main peer-reviewed trial used 3 ppm. These are not safety maxima. Community reports rarely identify peptide generation or actual concentration. Commonness does not mean population prevalence. No Matrixyl-specific online-product purity survey, poison-center series or contamination-rate study located. No verified vial sizes, water volumes, home storage recipe, microdosing protocol or injection cycle found. No specific PCAC decision, FDA warning letter or clear WADA ruling verified. Import and supply rules depend on the product. The 2026 meta-analysis mainly pooled oral collagen and included no Matrixyl intervention; it cannot validate pal-KTTKS.

Related to Matrixyl

• Argireline: A topical cosmetic peptide with small, mixed wrinkle studies and limited skin penetration.
• GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.

Matrixyl: the short version

Sources

• 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
• 503B Bulk Drug Substances List, FDA · FDA · 2026
• Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
• Peptide products, Therapeutic Goods Administration · TGA · 2026
• The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
• Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
• Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
• Consumer products: cosmetics, Office for Product Safety and Standards · 2025
• Allergens in Cosmetics, U.S. Food and Drug Administration · FDA
• Microbiological Safety and Cosmetics, U.S. Food and Drug Administration · FDA
• Notification of Cosmetics, Health Canada
• Wrinkle Treatments and Other Anti-aging Products, U.S. Food and Drug Administration
• Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials., Nukaly HY et al. · Frontiers in medicine · 2026
• Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis., Rodríguez D et al. · Cureus · 2026
• New Targets on Anti-wrinkles with Palmitoyl Pentapeptide-4: The Next Frontier in Anti-Aging Skincare, Lien L and Chen W · SOFW Journal · 2025

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.